DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Wednesday. The brokerage issued a hold rating on the stock.

Other equities research analysts have also issued reports about the stock. HC Wainwright boosted their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. JMP Securities restated a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a research report on Tuesday, December 10th.

DBV Technologies Trading Up 3.4 %

Shares of DBVT opened at $3.36 on Wednesday. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $9.73. The company has a market cap of $69.11 million, a price-to-earnings ratio of -0.75 and a beta of 0.64. The business’s fifty day simple moving average is $3.32 and its two-hundred day simple moving average is $3.86.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.